Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.

It seems like a long time ago that biotech companies dominated headlines with jaw-dropping funding rounds and initial public offerings. Case in point – immunotherapy firm Immunocore, whose roots can be traced back to University of Oxford, smashed European records with a $320m funding round in July 2015. As for flotations, Cellectis, a gene-editing company…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.